274 related articles for article (PubMed ID: 15831697)
61. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution.
Chou WC; Tang JL; Lin LI; Yao M; Tsay W; Chen CY; Wu SJ; Huang CF; Chiou RJ; Tseng MH; Lin DT; Lin KH; Chen YC; Tien HF
Cancer Res; 2006 Mar; 66(6):3310-6. PubMed ID: 16540685
[TBL] [Abstract][Full Text] [Related]
62. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation.
Schwäble J; Choudhary C; Thiede C; Tickenbrock L; Sargin B; Steur C; Rehage M; Rudat A; Brandts C; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 Mar; 105(5):2107-14. PubMed ID: 15536149
[TBL] [Abstract][Full Text] [Related]
63. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.
Falini B; Sportoletti P; Martelli MP
Curr Opin Oncol; 2009 Nov; 21(6):573-81. PubMed ID: 19770764
[TBL] [Abstract][Full Text] [Related]
64. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia.
Moreno I; Martín G; Bolufer P; Barragán E; Rueda E; Román J; Fernández P; León P; Mena A; Cervera J; Torres A; Sanz MA
Haematologica; 2003 Jan; 88(1):19-24. PubMed ID: 12551822
[TBL] [Abstract][Full Text] [Related]
65. FLT3 mutations in myeloid sarcoma.
Ansari-Lari MA; Yang CF; Tinawi-Aljundi R; Cooper L; Long P; Allan RH; Borowitz MJ; Berg KD; Murphy KM
Br J Haematol; 2004 Sep; 126(6):785-91. PubMed ID: 15352981
[TBL] [Abstract][Full Text] [Related]
66. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Smith BD; Levis M; Beran M; Giles F; Kantarjian H; Berg K; Murphy KM; Dauses T; Allebach J; Small D
Blood; 2004 May; 103(10):3669-76. PubMed ID: 14726387
[TBL] [Abstract][Full Text] [Related]
67. The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model.
Cheng K; Sportoletti P; Ito K; Clohessy JG; Teruya-Feldstein J; Kutok JL; Pandolfi PP
Blood; 2010 Apr; 115(16):3341-5. PubMed ID: 19666870
[TBL] [Abstract][Full Text] [Related]
68. Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival.
Zhang W; Zhao C; Zhao J; Zhu Y; Weng X; Chen Q; Sun H; Mi JQ; Li J; Zhu J; Chen Z; Pandolfi PP; Chen S; Yan X; Xu J
Theranostics; 2018; 8(16):4359-4371. PubMed ID: 30214626
[TBL] [Abstract][Full Text] [Related]
69. Gene rearrangements in bone marrow cells of patients with acute myelogenous leukemia.
Schmetzer HM; Braun S; Wiesner D; Duell T; Gerhartz HH; Mittermueller J
Acta Haematol; 2000; 103(3):125-34. PubMed ID: 10940650
[TBL] [Abstract][Full Text] [Related]
70. NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia.
Palmisano M; Grafone T; Ottaviani E; Testoni N; Baccarani M; Martinelli G
Haematologica; 2007 Sep; 92(9):1268-9. PubMed ID: 17768124
[TBL] [Abstract][Full Text] [Related]
71. Point mutations in the FLT3 gene in AML.
Griffin JD
Blood; 2001 Apr; 97(8):2193A-2193. PubMed ID: 11290575
[No Abstract] [Full Text] [Related]
72. Nucleophosmin: a versatile molecule associated with hematological malignancies.
Naoe T; Suzuki T; Kiyoi H; Urano T
Cancer Sci; 2006 Oct; 97(10):963-9. PubMed ID: 16984370
[TBL] [Abstract][Full Text] [Related]
73. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
Falini B; Macijewski K; Weiss T; Bacher U; Schnittger S; Kern W; Kohlmann A; Klein HU; Vignetti M; Piciocchi A; Fazi P; Martelli MP; Vitale A; Pileri S; Miesner M; Santucci A; Haferlach C; Mandelli F; Haferlach T
Blood; 2010 May; 115(18):3776-86. PubMed ID: 20203266
[TBL] [Abstract][Full Text] [Related]
74. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
Kühn MW; Song E; Feng Z; Sinha A; Chen CW; Deshpande AJ; Cusan M; Farnoud N; Mupo A; Grove C; Koche R; Bradner JE; de Stanchina E; Vassiliou GS; Hoshii T; Armstrong SA
Cancer Discov; 2016 Oct; 6(10):1166-1181. PubMed ID: 27535106
[TBL] [Abstract][Full Text] [Related]
75. [Nucleophosmin mutations in hematological malignancies - review].
Luo ZP; Zhang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):662-6. PubMed ID: 17605889
[TBL] [Abstract][Full Text] [Related]
76. FLT3/ITD mutation signaling includes suppression of SHP-1.
Chen P; Levis M; Brown P; Kim KT; Allebach J; Small D
J Biol Chem; 2005 Feb; 280(7):5361-9. PubMed ID: 15574429
[TBL] [Abstract][Full Text] [Related]
77. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.
Fröhling S; Schlenk RF; Breitruck J; Benner A; Kreitmeier S; Tobis K; Döhner H; Döhner K;
Blood; 2002 Dec; 100(13):4372-80. PubMed ID: 12393388
[TBL] [Abstract][Full Text] [Related]
78. FLT3 Inhibitors in the Treatment of AML.
Gilliland DG
Clin Adv Hematol Oncol; 2004 Nov; 2(11):708-10. PubMed ID: 16163256
[No Abstract] [Full Text] [Related]
79. FLT3 and its role in the pathogenesis of acute myeloid leukaemia.
Reilly JT
Leuk Lymphoma; 2003 Jan; 44(1):1-7. PubMed ID: 12691136
[TBL] [Abstract][Full Text] [Related]
80. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors.
Hunter HM; Pallis M; Seedhouse CH; Grundy M; Gray C; Russell NH
Br J Haematol; 2004 Oct; 127(1):26-33. PubMed ID: 15384974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]